- Home
- UFPI vs BPMC Comparison
UFPI vs BPMC Comparison
Compare UFPI & BPMC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UFPI
- BPMC
- Stock Information
- Founded
- UFPI 1955
- BPMC 2008
- Country
- UFPI United States
- BPMC United States
- Employees
- UFPI N/A
- BPMC N/A
- Industry
- UFPI Forest Products
- BPMC Biotechnology: Pharmaceutical Preparations
- Sector
- UFPI Basic Materials
- BPMC Health Care
- Exchange
- UFPI Nasdaq
- BPMC Nasdaq
- Market Cap
- UFPI 6.5B
- BPMC 5.8B
- IPO Year
- UFPI 1993
- BPMC 2015
- Fundamental
- Price
- UFPI $104.78
- BPMC $84.69
- Analyst Decision
- UFPI Strong Buy
- BPMC Buy
- Analyst Count
- UFPI 4
- BPMC 22
- Target Price
- UFPI $143.00
- BPMC $124.48
- AVG Volume (30 Days)
- UFPI 583.8K
- BPMC 1.2M
- Earning Date
- UFPI 04-28-2025
- BPMC 05-01-2025
- Dividend Yield
- UFPI 1.34%
- BPMC N/A
- EPS Growth
- UFPI N/A
- BPMC N/A
- EPS
- UFPI 6.77
- BPMC N/A
- Revenue
- UFPI $6,652,309,000.00
- BPMC $508,824,000.00
- Revenue This Year
- UFPI $4.05
- BPMC $45.70
- Revenue Next Year
- UFPI $5.89
- BPMC $31.83
- P/E Ratio
- UFPI $15.48
- BPMC N/A
- Revenue Growth
- UFPI N/A
- BPMC 104.04
- 52 Week Low
- UFPI $99.42
- BPMC $73.04
- 52 Week High
- UFPI $141.33
- BPMC $121.90
- Technical
- Relative Strength Index (RSI)
- UFPI 45.98
- BPMC 47.15
- Support Level
- UFPI $102.15
- BPMC $78.66
- Resistance Level
- UFPI $108.11
- BPMC $83.50
- Average True Range (ATR)
- UFPI 4.75
- BPMC 5.00
- MACD
- UFPI -0.05
- BPMC 0.20
- Stochastic Oscillator
- UFPI 53.02
- BPMC 67.15
About UFPI UFP Industries Inc.
UFP Industries Inc is a supplier of lumber to the manufactured housing industry. Today UFP Industries is a multibillion-dollar holding company with subsidiaries around the globe that serve three markets: retail, packaging and construction. Its business segments consist of UFP Retail Solutions, UFP Packaging, UFP Construction, All other and Corporate.
About BPMC Blueprint Medicines Corporation
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates includes AYVAKIT for the treatment of systemic mastocytosis, BLU-808 a potential treatment for mast cell disorders, including chronic urticaria, sleep disruption and other related diseases. It also has other drugs in its pipeline such as BLU-956, BLU-222 for treatment of breast cancer.